Get the Stockscreener App
3.24
3.85%
0.12
After Hours:
3.19
-0.05
-1.54%
Anavex Life Sciences Corporation stock is traded at $3.24, with a volume of 993.53K.
It is up +3.85% in the last 24 hours and down -30.32% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$3.12
Open:
$3.15
24h Volume:
993.53K
Relative Volume:
0.66
Market Cap:
$300.26M
Revenue:
-
Net Income/Loss:
$-39.95M
P/E Ratio:
-6.9692
EPS:
-0.4649
Net Cash Flow:
$-34.08M
1W Performance:
+6.58%
1M Performance:
-30.32%
6M Performance:
-64.12%
1Y Performance:
-64.47%
1-Day Range:
$3.11
$3.25
1-Week Range:
$2.905
$3.305
52-Week Range:
$2.61
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
3.24 | 289.14M | 0 | -39.95M | -34.08M | -0.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology between Autism and Alzheimer's disease - marketscreener.com
Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference - MarketBeat
Anavex Life Sciences Advances Blarcamesine Research, Highlighting Shared Autophagy Mechanisms in Autism and Alzheimer’s Disease - Quiver Quantitative
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease - Anavex Life Sciences
Aug Rallies: Does Anavex Life Sciences Corp have strong fundamentalsMarket Activity Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Shareholders to Connect - ACCESS Newswire
AVXL Technical Analysis | Trend, Signals & Chart Patterns | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aug Retail: Is Anavex Life Sciences Corp stock trending bullish2026 Short Interest & Reliable Volume Spike Alerts - baoquankhu1.vn
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Anavex Life Sciences Corp. to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-04-05 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect - ACCESS Newswire
Anavex Life Sciences Corp. (AVXL) stock price, news, quote and history - Yahoo Finance UK
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect | NDAQ:AVXL | Press Release - stockhouse.com
3 Promising Penny Stocks With At Least $200M Market Cap - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Anavex Life Sciences Corp (12X1.HM) Recent Insider Transactions - Yahoo! Finance Canada
AVXL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Anavex Life Sciences Provides Comprehensive Regulatory Update - The Manila Times
After withdrawing its EU filing, Anavex keeps Alzheimer’s drug in talks - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Stockholders to Connect - ACCESS Newswire
Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-27 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Anavex Life Sciences Under Investigation for Securities Fraud - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - PR Newswire
Vanguard reports 0 AVXL shares after internal realignment (AVXL) - Stock Titan
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Sahm
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip? - Yahoo Finance
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation - Yahoo Finance
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease - Bitget
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug - Stocktwits
Anavex Life Sciences provides update on regulatory review in the EU for blarcamesine to treat early Alzheimer's disease - marketscreener.com
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com Australia
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences stock tumbles after EU filing withdrawal - Investing.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):